News | July 02, 2021
Sandu Pharmaceuticals Q4FY21 PAT at Rs. 46.14 lakhs
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
Sun Pharma has committed Rs. 100 crores towards these initiatives
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The company has reported total income of Rs.355.43 crores during FY 2020-21
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
The company has predominantly built a portfolio into veterinary products
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated
